Shuwen Announces Peer-Reviewed Publication of Data Demonstrating the Potential of its Breakthrough Preeclampsia Detection Device in Unselected Women

Shuwen Biotech Co. Ltd., a China-based leader in innovative diagnostics announced today the peer-reviewed publication of data highlighting the potential of its breakthrough point-of-care test in rapidly diagnosing Preeclampsia among women who are admitted to the hospital. The paper, entitled “Late pregnancy screening for preeclampsia with a urinary point-of-care test for misfolded proteins”, was written by collaborators from China Medical University’s Shengjing Hospital and Columbia University Medical Center in New York and demonstrates the ability of the test to detect preeclampsia at a high level of accuracy in women admitted to the hospital for any reason. The findings included over 1,500 women and were published in the peer-reviewed journal PLOS One.

According to the WHO, almost 80,000 women die and half a million pregnancies are lost each year from preeclampsia and related hypertensive disorders. Preeclampsia affects 2–8% of pregnancies worldwide and in places such as Latin America, it represents the number one cause of maternal death. Unfortunately, in the majority of cases, symptoms of preeclampsia are not noticeable until it has progressed, emphasizing the major unmet need for an objective and effective test, particularly in low- and middle-income countries. The kit is a highly attractive tool for healthcare professionals, patients, and governments globally to rapidly, cost-effectively, non-invasively and accurately diagnose a condition which otherwise often is misdiagnosed and requires lengthy hospitalizations and monitoring for patients.

In the study, researchers collected urine from 1,532 pregnant women hospitalized at 20-41 weeks gestation, regardless of the reason for hospitalization, and prospectively tested misfolded proteins in pregnant women’s urine using Shuwen’s patented point-of-care test device. Results showed a very high screening performance in a first-to-be studied Chinese population.

Shuwen’s Chairman and CEO, Jay Z. Zhang, M.S., J.D said, “We at Shuwen are grateful to our collaborators for their hard and diligent work over the last few years to demonstrate how our Company principles of innovation, patent protection, and international collaboration can lead to tangible and outstanding clinical value for patients and other stakeholders. The data published in this paper reinforce the clinical importance of point-of-care testing in preeclampsia globally. We look forward to continuing to build this important clinical body of evidence.”

The test kit is already CE marked by Shuwen and available for sales and clinical use in an increasing number of countries as regulatory processes progress across the world.

Medical Device News Magazine
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Michael Dabrowski, CEO of Pelago Bioscience "We are grateful to the University of Edinburgh in their acknowledgement of our Patent. I encourage the drug discovery community to engage with Pelago Bioscience to explore the value that our patented CETSA technology and services can bring to enhance their drug discovery efforts.
The Thermo Scientific™ Dionex™ Inuvion™ Ion Chromatography (IC) system, helping to make ion analysis simpler and more intuitive for labs of all sizes. The new analytical instrument is designed to be easily reconfigurable, providing those who require determination of ionic and small polar compounds with a one stop shop for consistent, reliable ion analysis.
This new collaboration is another example of Blacksmith's creative deal-making with top tier partners that bring expertise to the table which helps de-risk and accelerate scientific discoveries for the development of valuable products.
Heparin Sodium 2,000 units in 0.9% Sodium Chloride Injection 1,000 mL (2 units/mL), is indicated as an anticoagulant to maintain catheter patency.
Through this agreement, RaySearch acquires full ownership of all rights to the product DrugLog for its application in the field of oncology, including the measuring device, calibration parameters, source code, as well as intellectual property rights.

By using this website you agree to accept Medical Device News Magazine Privacy Policy